Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement

2025-12-12 16:28:31 ET

The last time I spoke about Immunovant ( IMVT ) it was with respect to a Seeking Alpha article entitled " Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward ". With respect to this article, I noted that the company was able to meet the primary endpoint of the phase 3 study in that patients who took batoclimab were able to achieve a 5.6 improvement change from baseline in the MG-ADL score. In addition, I noted that the company was gearing up to release results from the phase 3 studies using batoclimab to treat patients with active thyroid eye disease [TED]. As an update on this, the company was set to release data from one of the first two phase 3 studies for these patients with active TED before the end of 2025. However, due to the competitive landscape nature of this indication, it has changed its mind and is instead going to release topline results concurrently in the 1st half of 2026....

Read the full article on Seeking Alpha

For further details see: